STAT+: Medicare quietly gave blockbuster AbbVie drug seven extra years before price negotiations, advocacy group asserts

AI justification

Policy delay enables prolonged healthcare inequity and corporate profit over patient rights. | The delay in Medicare price negotiations undermines equitable access to essential healthcare (SDG 3) and exacerbates inequalities (SDG 10) by prioritizing pharmaceutical industry profits over patient affordability. It violates the right to adequate health (UDHR Article 25) and weakens institutional accountability (SDG 16). No countervailing positive aspects are identified in the action itself.